Glaxo holds its breath

[cafead]

via Though the separation of Glaxosmithkline's consumer care business Haleon is grabbing much of the attention, the group has another, strictly biotech, catalyst coming up. A pivotal trial of its respiratory syncytial virus (RSV) vaccine in the elderly is due to report by mid-year, and a great deal is riding on the results.

article source